Vytrus Biotech increases its net profit by more than 100% in 2021.

April 26, 2022

Vytrus Biotech has closed 2021 with the best results in its history, increasing its net profit by more than 100% compared to 2020.

Following the issuance and publication of the 2021 audit report, the biotech company presents the best numbers and ratios in its history. Its turnover jumped by 64% in 2021 compared to the previous year, reaching a turnover of €2.8 million, while EBITDA increased by 91% to €1.13 million. Vytrus has thus increased its sales by 133% in the two years of the Covid-19 pandemic.

The IPO process has involved numerous internal changes and we have carried out a multitude of procedures such as audits or due diligence of all kinds, among others. So, it has been a very intense few months, but it has been worth it to be listed on the market, an objective that we had in mind for a long time.
Albert Jané
CEO, COO and cofounder

Doubles its market value in its first month of trading

On March 15, following the traditional bell ringing held at the Barcelona Stock Exchange, Vytrus became the second company in 2022 in Spain to make the leap to BME Growth, the stock market for SMEs. The company, which debuts as a non-placement listing under the trading code “VYT”, has increased its market value by more than 100% during its first month of trading, rising from a starting price of €12.2 million to a current value of almost €24.2 million, with a price as of April 25 of €3.54 per share from the initial reference value of €1.72 per share.

This evolution of the share value reflects the positive reception of Vytrus by the market and even more so within the current framework of uncertainty experienced by the global stock markets.

More information is available in the investors area of the website.